CEO John Huemoeller of Axim Biotechnologies, Inc. (OTCQB: AXIM), joins the show to talk about becoming the new CEO, how his business background will help in executing the new business plan, and bringing new pharmaceutical products to market.

cannabinoid bioscience # discovery and commercialization # solid fiscal strategy # Clinical development programs # broad IP portfolio # reduced side effects # cannabinoid research and development # cannabis # patent # Cannaway # chewing gum